Monitoring CAR‑BCMA immune cells in multiple myeloma
CAR-T Immunomonitoring in Multiple Myeloma
NA · Poitiers University Hospital · NCT07342179
This project will test whether tracking CAR‑BCMA cells and related immune markers in blood and bone marrow can help predict which multiple myeloma patients respond to CAR‑T therapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Poitiers University Hospital (other) |
| Drugs / interventions | CAR-T, CAR T, chimeric antigen receptor, CART |
| Locations | 1 site (Poitiers) |
| Trial ID | NCT07342179 on ClinicalTrials.gov |
What this trial studies
Researchers will collect clinical data from diagnosis, relapses, prior treatments, and details around CAR‑T therapy, and will take additional blood and bone marrow samples before and up to one year after CAR‑T infusion. Samples will be sent to centralized laboratories to measure CAR‑BCMA cell persistence and the expression of surface proteins CD95 and CD95L as well as soluble CD95L in serum. The project is conducted in collaboration with the IRMETIST INSERM unit at the University of Poitiers and aims to identify cellular immunological markers that correlate with effective responses to CAR‑T treatment. Results will be used to inform patient follow‑up and may guide future personalized immunotherapy approaches.
Who should consider this trial
Good fit: Adults (18+) with a diagnosis of multiple myeloma who are scheduled to receive CAR‑T cell therapy in accordance with French authorizations and who can attend Poitiers for extra blood and bone marrow sampling are ideal candidates.
Not a fit: Patients who are not receiving CAR‑T therapy, who cannot comply with repeated sampling, or who are in excluded vulnerable groups (for example pregnant individuals or those under legal guardianship) are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this could help doctors predict who is most likely to benefit from CAR‑T therapy and tailor follow‑up or additional treatments accordingly.
How similar studies have performed: Previous work has shown that long‑term persistence of CAR‑T cells often correlates with better outcomes, but using CD95/CD95L profiling as predictive markers is a more novel approach with limited prior validation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 and over * Patient with Multiple Myeloma according to international recommendations, * Patient about to receive CAR-T cell therapy in accordance with the rules and authorizations in France. Exclusion Criteria: * Patients with severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study. * Simultaneous participation in another study with an ongoing exclusion period. * Individuals receiving enhanced protection, namely minors, pregnant and/or breastfeeding women, individuals deprived of their liberty by a judicial or administrative decision, individuals residing in a healthcare or social care facility, adults under legal guardianship, and finally, patients in emergency situations
Where this trial is running
Poitiers
- Chu de Poitiers — Poitiers, France (RECRUITING)
Study contacts
- Study coordinator: ARTHUR BOBIN
- Email: arthur.bobin@chu-poitiers.fr
- Phone: 0033549444201
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Myeloma